Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — FY2022 Earnings Presentation
19 slides from Indivior Pharmaceuticals's earnings presentation, Feb 16, 2023
Slide 1: Q4/FY 2022 Results
Q4/FY 2022 Results February 16, 2023
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group’s financial guidance for 2023 and its medium- and long-term growth outlook; expectations for sales levels
Slide 3: Agenda
Agenda Mark Crossley Overview & Strategic Priorities Update Christian Heidbreder R&D Update Ryan Preblick Q4/FY 2022 Performance & FY 2023 Guidance Mark Crossley Conclusion All Q&A
Slide 4: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 5: FY 2022 key messages
FY 2022 key messages Continued strong execution in FY 2022 – Total NR1 up 14% driven by SUBLOCADE®; ( SUBLOCADE NR grew 67% to $408m FY 2023 guidance introduced – expect top-line growth and positive operating leverage, consistent with medium-term profitable growth framework Pending Opiant Pharmaceut
Slide 6: Proactively addressing legacy litigation
Proactively addressing legacy litigation Initial mediation sessions in late January 2023 regarding legacy civil multidistrict antitrust litigation provided the Group with new information on the previously disclosed contingent liability. Accordingly, the Group recorded an exceptional provision of $29
Slide 7: Executing clear strategies for value creation
Executing clear strategies for value creation 1 2 3 4 Grow Build & Optimize SUBLOCADE Diversify Progress Operating >$1.5bn Revenue Pipeline Model • Peak NR increased to >$1.5bn (expect • 11/14/22 agreement to acquire • AELIS AEF0117 (CUD4): Phase 2b study • Maintained financial flexibility; $991m >$
Slide 8: Medium-term profitable growth framework
Medium-term profitable growth framework Attractive Growth Positive Operating Strengthening Profile Leverage Cash Flow 8
Slide 9: Christian Heidbreder, Chief Scientific Officer
Christian Heidbreder Chief Scientific Officer
Slide 10: SUBLOCADE strategic R&D and medical priorities 2023
SUBLOCADE strategic R&D and medical priorities 2023 Label updates Long-term Patient collaborations Insights & (e.g., advocacy RECOVER, CoLAB, EXPO) Breaking Barriers Peer-reviewed Externally publications & Sponsored Conferences Studies (ESS) Long-term Real World efficacy & Evidence safety (LTES) (RW
Slide 11: Most recent peer-reviewed publications
Most recent peer-reviewed publications Long‐term recovery from opioid use disorder: recovery subgroups, transition states and their association with substance use, treatment and quality of life - Craft - Addiction - Wiley Online Library Impact of medications for opioid use disorder on healthcare res
Slide 12: SUBLOCADE, SUBOXONE Film (ex-US) & PERSERIS
SUBLOCADE, SUBOXONE Film (ex-US) & PERSERIS SUBUTEX® prolonged-release (PR) PERSERIS (risperidone) for extended- SUBOXONE film (Ex US) solution for injection release injectable suspension • Regulatory approvals granted in 11 • Regulatory approvals granted in • Two FDA approvals of Prior Approval MoW
Slide 13: Pipeline activities
Pipeline activities AUD Nonclinical OUD Clinical Phase 1 CUD Clinical Phase 2b INDV-1000 INDV-2000 AEF01171 GABA-B +VE ALLOSTERIC MODULATOR SELECTIVE OX1 RECEPTOR ANTAGONIST CB1 -VE ALLOSTERIC MODULATOR • Characterization of two lead • Objectives for 2023 are to: • Aelis Farma achieved first subject
Slide 14: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 15: FY 2022 financial highlights
FY 2022 financial highlights Takeaways Operating Results – Reported and Adjusted2 ➤ Top-line NR growth of 14% vs. FY 2021 $ mil FY 22 FY 21 Change Net Revenue: 901 791 14% ✓ US NR up 21% US 731 603 21% ROW3 170 188 (10%) ✓ ROW NR down 10% including FX (up 1% Gross Profit: 742 664 12% Adjusted exclud
Slide 16: Cash & borrowing position
Cash & borrowing position Cash & Borrowing Takeaways Total gross cash & investments of $991m1: ➤ Cash and investments primarily held in USD FY 22 FY 21 ($ in mil.) ➤ Approximately $90m used for share repurchases during FY 2022 at an average price of 1,537p Cash & Cash Equivalents $774 $1,102 ST & LT
Slide 17: FY 2023 guidance introduced
FY 2023 guidance introduced Excludes impacts from the pending transactions with Opiant Pharmaceuticals Additional Top-Line Assumptions FY 2023 Guidance1 ($ in mil.) ➤ Underlying BMAT market growth of mid- to high-single digits ➤ US SUBOXONE Film • Anticipated formulary decisions expected to impact s
Slide 18: Appendix
Appendix 18
Slide 19: Financial Reconciliation: FY 2022 & FY 2021
Financial Reconciliation: FY 2022 & FY 2021 FY 2022 FY 2021 ($ in mil. at Actual FX ) Net Income / (Loss) (53) 205 Net interest (expense) / income 10 23 Taxation (42) (15) Operating Profit / (Loss) (85) 213 Adjustments 297 (26) Adjusted Operating Profit / (Loss) 212 187 FY 2022 Notes: $290m impact f